24/7 Market News Snapshot 30 September, 2025 – CollPlant Biotechnologies Ltd Ordinary Shares (NASDAQ:CLGN)

September 30, 2025

DENVER, Colo., 30 September, 2025 (www.247marketnews.com) – (NASDAQ:CLGN) are discussed in this article.
CollPlant Biotechnologies Ltd (CLGN) has recently experienced a notable decline in its stock price, trading at approximately $2.998 in pre-market, which represents a drop of about 2.97% from the previous close of $3.090. The trading volume has surged to 1.72 million shares, reflecting increased investor activity amid shifting market sentiment. Analysts indicate that the stock continues to face challenges below the significant $3.00 resistance level, with key support anticipated around $2.90. Market participants are encouraged to monitor for patterns of reversal or continuation in the coming sessions to gain insights into the stock’s short-term trajectory.

In a contrasting development, CollPlant is advancing its innovative photocurable dermal filler into clinical trials following the successful completion of its non-clinical program. This novel product is poised to revolutionize the aesthetic medicine sector by integrating precise contouring, structural support, and tissue regeneration. The advanced formulation combines hyaluronic acid with CollPlant’s proprietary recombinant human collagen (rhCollagen), allowing for meticulous application through a fine needle. Once the product is activated with a specialized illumination device, it transforms into a durable, cohesive implant that maintains its shape even under mechanical stress.

Yehiel Tal, Chief Executive Officer of CollPlant, conveyed optimism about this milestone, emphasizing the potential to redefine aesthetic care standards with this photocurable filler. The extensive non-clinical evaluations, including rigorous safety assessments and a comprehensive one-year durability study, have laid a solid foundation for further clinical developments. Additionally, CollPlant is enhancing its manufacturing capabilities in preparation for these upcoming trials, supported by a global commercialization agreement with a prominent player in the dermal and soft tissue filler market, setting the stage for significant advancements in medical aesthetics.

Related news for (CLGN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.